NAFLD与肝细胞癌的相关性研究进展*

doi:10.3969/j.issn.1672-5069.2018.05.046

摘要/Abstract

摘要： 非酒精性脂肪性肝病（NAFLD）已成为世界范围内最常见的慢性肝脏疾病,被认为是代谢综合征在肝脏的表现,其疾病谱从轻微肝细胞脂肪变性到非酒精性脂肪性肝炎（NASH）,进一步可发展为肝硬化或肝细胞癌（HCC）。随着肥胖及胰岛素抵抗问题的日益严重,NAFLD、NASH及其相关肝硬化、肝癌患者也日益增多。近年来研究表明,NASH可不经肝硬化阶段直接发展为HCC,具体机制尚不明确。

关键词: 非酒精性脂肪性肝病, 肝细胞癌, 代谢综合征

Abstract: Non-alcoholic fatty liver disease （NAFLD）,involvement of metabolic syndrome,is being the most common liver disease worldwide. The spectrum of NAFLD ranges from simple steatosis to NASH,finally leading to liver cirrhosis and hepatocellular carcinoma（HCC）. As the obesity is becoming global problem,the incidence of NAFLD,NASH and NAFLD/NASH-associated cirrhosis and NAFLD/NASH-associated HCC is increasing gradually. In recent years,many scholars believe that HCC might arise in the absence of overt cirrhosis in patients with NASH,and the mechanism for the switch remains elusive. The review will focus on the relationship between NAFLD and HCC.

Key words: Nonalcoholic fatty liver disease, Hepatocellular carcinoma, Metabolic syndrome

邴浩综述, 李异玲审校. NAFLD与肝细胞癌的相关性研究进展^*[J]. 实用肝脏病杂志, 2018, 21(5): 821-824.

Bing Hao, Li Yiling.. Correlation between non-alcoholic fatty liver disease and hepatocellular carcinoma:Fact or fiction[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 821-824.

参考文献

[1] Hassan K,Bhalla V,El Regal ME,et al.Nonalcoholic fatty liver disease:A comprehensive review of a growing epidemic. World J Gastroenterol,2014, 20(34): 12082-12101.
[2] Younossi ZM,Koenig AB,Abdelatif D,et al.Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence,incidence,and outcomes. Hepatology,2016,64(1): 73-84.
[3] Fan J.Epidemiology of alcoholic and nonalcoholic fatty liver disease in China. J Gastroenterol Hepatol,2013,28:11-17.
[4] De Minicis S,Day C,Svegliati-Baroni G.From NAFLD to NASH and HCC:Pathogenetic mechanisms and therapeutic insights. Curr Pharmaceut Des,2013,19(29):5239-5249.
[5] Powell EE,Cooksley WG,Hanson R, et al.The natural history of nonalcoholic steatohepatitis:A follow-up study of forty-two patients for up to 21 years. Hepatology,1990,11(1):74-80.
[6] Rosmorduc O,Fartoux L. HCC and NASH: How strong is the clinical demonstration Clin Res Hepatol Gastroenterol,2012,36(3):202-208.
[7] Sanyal A,Poklepovic A,Moyneur E,et al.Population-based risk factors and resource utilization for HCC: US perspective. Curr Med Res Opin,2010,26(9):2183-2191.
[8] White DL,Kanwal F,El Serag HB.Non-alcoholic fatty liver disease and hepatocellular cancer:A systematic review. Clin Gastroenterol Hepatol,2012,10(12):1342-1359.
[9] Said A,Ghufran A.Epidemic of non-alcoholic fatty liver disease and hepatocellular carcinoma. World J Clin Oncol,2017,8(6):429-436.
[10] Duan X,Zhang L,Fan J,et al.NAFLD leads to liver cancer: Do we have sufficient evidence. Cancer Lett,2014,345(2):230-234.
[11] Ascha MS,Hanouneh IA,Lopez R,et al.The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology,2010,51(6):1972-1978.
[12] Bugianesi E,Leone N,Vanni E,et al.Expanding the natural history of nonalcoholic steatohepatitis:From cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology,2002,123(1):134-140.
[13] Marrero JA,Fontana RJ,Su GL,et al.NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology,2002,36(6):1349-1354.
[14] Michelotti GA,Machado MV,Diehl AM.NAFLD,NASH and liver cancer. Nature Reviews. Gastroenterol Hepatol,2013,10(11):656-665.
[15] Alexander J,Torbenson M,Wu TT,et al.Nonalcoholic fatty liver disease contributes to hepatocellular carcinoma in non-cirrhotic liver:A clinical and pathological study. Gastroenterol Hepatol,2013,28(5):848-854.
[16] Polesel J,Zucchetto A,Montella M,et al.The impact of obesity and diabetes mellitus on the risk of hepatocellular carcinoma. Ann Oncol,2008,20(2):353-357.
[17] Calle EE,Rodriguez C,Walker-Thurmond K,et al.Overweight, obesity,and mortality from cancer in a prospectively studied cohort of US. N Engl J Med,2003,348(17):1625-1638.
[18] Yu J,Shen J,Sun TT,et al.Obesity,insulin resistance,NASH and hepatocellular carcinoma. Sem Cancer Biol,2013,23(6):483-491.
[19] Wang P,Kang DH,Cao W,et al.Diabetes mellitus and risk of hepatocellular carcinoma:A systematic review and meta-analysis. Diabetes Metab Res Rev,2012,28(2):109-122.
[20] Hassan MM,Hwang LY,Hatten CJ,et al.Risk factors for hepatocellular carcinoma: Synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology,2002,36(5): 1206-1213.
[21] Chen CL,Yang HI,Yang WS,et al.Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection:A follow-up study in Taiwan. Gastroenterology,2008,135(1): 111-121.
[22] Park EJ,Lee JH,Yu G,et al.Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell,2010,140(2):197-208.
[23] Kamada Y,Matsumoto H,Tamura S,et al.Hypoadiponectinemia accelerates hepatic tumor formation in a nonalcoholic steatohepatitis mouse model. Hepatology,2007,47(4):556-564.
[24] Margini C,Dufour JF.The story of HCC in NAFLD:From epidemiology,across pathogenesis,to prevention and treatment. Liver Int,2016,36(3):317-324.
[25] Starley BQ,Calcagno CJ,Harrison SA.Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection. Hepatology,2010, 1(5):1820-1832.
[26] Sorrentino P,D Angelo S,Ferbo U,et al. Liver iron excess in patients with hepatocellular carcinoma developed on non-alcoholic steato-hepatitis. Hepatology,2009,50(2):351-357.
[27] Shen JH,Li YL,Li D, et al.The rs738409(I148M) variant of the PNPLA3 gene and cirrhosis:A meta-analysis. J Lipid Res,2015,56(1):167-175.
[28] Trepo E,Romeo S,Zucman-Rossi J,et al.PNPLA3 gene in liver diseases. J Hepatol,2016,65(2):399-412.
[29] Jang WY,Bae KB,Kim SH,et al.Overexpression of Jazf1 reduces body weight gain and regulates lipid metabolism in high fat diet. Bioch Biophy Res Commun,2014,444(3):296-301.
[30] Alharbi KK,Ali KI,Syed R,et al.Association of JAZF1 and TSPAN8/LGR5 variants in relation to type 2 diabetes mellitus in a Saudi population. Diabetol Metab Syndr,2015,7(1):92.
[31] Ueyama M,Nishida N,Korenaga M,et al.The impact of PNPLA3 and JAZF1 on hepatocellular carcinoma in non-viral hepatitis patients with type 2 diabetes mellitus. Gastroenterology,2016,51(4):370-379.
[32] Kozlitina J,Smagris E,Stender S,et al.Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet,2014,46(4):352-356.
[33] Falleti E,Cussigh A,Cmet S,et al.PNPLA3 rs738409 and TM6SF2 rs58542926 variants increase the risk of hepatocellular carcinoma in alcoholic cirrhosis. Dig Liver Dis,2016,48(1):69-75.
[34] Paradis V,Albuquerque M,Mebarki M,et al.Cullin7:a new gene involved in liver carcinogenesis related to metabolic syndrome. Gut,2013,62(6):911-919.
[35] Weinmann A,Alt Y,Koch S,et al.Treatment and survival of non-alcoholic steatohepatitis associated hepatocellular carcinoma. BMC Cancer,2015,15(1):210.
[36] Piguet AC,Saran U,Simillion C,et al.Regular exercise decreases liver tumors development in hepatocyte-specifc PTEN-defcient mice independently of steatosis. Hepatology,2015,62(6):1296-1303.

NAFLD与肝细胞癌的相关性研究进展^*

Correlation between non-alcoholic fatty liver disease and hepatocellular carcinoma:Fact or fiction

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	中国研究型医院学会肝病专业委员会, 中国医师协会脂肪性肝病专家委员会. 脂肪性肝病诊疗规范化的专家建议（2019年修订版）[J]. 实用肝脏病杂志, 2019, 22(6): 787-792.
[2]	任俞霏, 陈小青, 孔维宗, 王迎春. 丹酚酸B对非酒精性脂肪性肝病细胞模型自噬功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 804-807.
[3]	李颖怡, 郭翠芬, 章瑞南, 汪保灿, 潘勤, 汪余勤, 曹海霞, 范建高. ALDH2 rs671基因多态性与非酒精性脂肪性肝病相关性研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 848-851.
[4]	邢欣, 魏重操, 周咪咪, 李小玲, 邓江, 鲁晓岚. 牛磺熊去氧胆酸与熊去氧胆酸治疗非酒精性脂肪性肝病患者疗效和安全性的Meta分析[J]. 实用肝脏病杂志, 2019, 22(6): 852-855.
[5]	曹策, 郁义星, 王贝贝, 赵卫峰. 增强磁共振成像联合血清甲胎蛋白和脱-γ-羧基凝血酶原诊断肝细胞癌临床价值探讨[J]. 实用肝脏病杂志, 2019, 22(6): 896-899.
[6]	张胥磊, 杨庆余, 韩秋玉, 缪鋆鋆, 蔡仁诚, 马亦旻. 自拟中药治疗非酒精性脂肪性肝病患者血清炎症反应指标水平的变化*[J]. 实用肝脏病杂志, 2019, 22(5): 660-663.
[7]	朱俊, 丁莹, 王世清, 张野, 刘野, 刘泽刚. 围手术期应用乌司他丁治疗对肝细胞癌患者肝切除术后外周血Th22细胞百分比和血浆白细胞介素-22的影响*[J]. 实用肝脏病杂志, 2019, 22(5): 720-723.
[8]	王刚, 赵洪波, 朱亚玲, 蒋保三, 张越美, 刁勇. 基于数据库分析肝细胞癌细胞XPO5基因水平变化及其临床意义*[J]. 实用肝脏病杂志, 2019, 22(5): 724-727.
[9]	张兰华, 邵琴, 夏振娟. 非酒精性脂肪性肝病儿童血清25-（OH）D3和IL-17水平变化初步研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 522-525.
[10]	谢晓, 刘婷, 董志霞, 夏幼辰, 张启迪, 曲颖, 蔡晓波, 徐铭益, 陆伦根. FibroTouch检测肝脏受控衰减参数对肝脂肪变的诊断价值分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 526-529.
[11]	戴青云, 王润东, 荚卫东. 术前预后营养指数评估肝细胞癌患者肝切除术后早期肿瘤复发价值探讨^*[J]. 实用肝脏病杂志, 2019, 22(4): 561-564.
[12]	杨富存, 尚怀学, 盖永浩. 钆塞酸二钠增强磁共振扫描诊断肝脏局灶性病变研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 577-580.
[13]	彭新健, 肖玉辉, 许斯鼎, 石荣跃, 王耀政, 王瑜琳. 放射性肝损伤患者肝脏磁共振扩散加权成像表现特征分析[J]. 实用肝脏病杂志, 2019, 22(3): 373-376.
[14]	符亮, 吴冬冰, 纪新尊, 万鸿兴, 李文刚, 饶卉明, 钟静, 江婷婷. 超声定量评估非酒精性脂肪性肝病患者肝脏ARFI值对显著NASH的诊断价值分析[J]. 实用肝脏病杂志, 2019, 22(3): 377-380.
[15]	乔志忠. 超声造影定量分析鉴别肝脏局灶性结节性增生与原发性肝癌初步探讨[J]. 实用肝脏病杂志, 2019, 22(3): 421-424.